Bisphosphonates May Be Useful as Palliative Measure in Selected Patients
the ONA take:
Bisphosphonates may improve symptoms of hypercalcemia and prolong survival in patients with malignancy-associated hypercalcemia receiving palliative care, a new study published online ahead of print in the journal Supportive Care in Cancer has shown.
Because hypercalcemia can be a potentially fatal paraneoplastic complication of malignancy, researchers sought to determine the reversibility of hypercalcemia amongst patients not receiving treatment for their underlying malignancy and assess whether calcium correction improves symptoms.
For the study, researchers analyzed data from 63 patients with evidence of malignancy-associated hypercalcemia being treated with bisphosphonates. Results showed that 36 of the 63 participants achieved normal calcium levels following treatment with an intravenous bisphosphonate.
Researchers found that history of hypercalcemia in the past, age, and albumin levels impacted whether patients achieved a complete response. The study also demonstrated that a reduction in calcium level was associated with significantly improved survival and symptoms regardless of whether patients achieved normal calcium levels.
Malignancy-associated hypercalcemia typically manifests during the advanced phase of cancer, when the life expectancy of patients ranges from weeks to months.
Although bisphosphonates are the mainstay of treatment for this complication, they are not typically used in a palliative population.
Bisphosphonates may improve symptoms of hypercalcemia and prolong survival in patients receiving palliative care.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|